Bayer's Supreme Court Victory and $5B Bond Come With a Fitch Warning and a Stalled Settlement Hearing

Bayer gains legal tailwind from Supreme Court preemption ruling and raises $5B bond, but Fitch keeps negative outlook due to litigation cash needs and rising debt.

Bayer pulled off a rare double this week, securing a new $5 billion bond and a decisive Supreme Court win in the glyphosate saga, but the rating agency Fitch has made clear that the legal progress has yet to ease the strain on the company's balance sheet. The stock closed at €48.17 on Friday, up 1.35% on the day and extending a year-to-date rally of 30.15%.

A Landmark Preemption Ruling Reshapes the Legal Landscape

The U.S. Supreme Court ruled 7-2 on June 25 in favor of Bayer's argument that federal approval of glyphosate by the Environmental Protection Agency preempts state-level failure-to-warn claims. The decision is widely seen as a watershed moment in the nearly decade-old Roundup litigation, which has already cost Bayer more than $10 billion in settlements and legal fees. JPMorgan promptly reaffirmed its "Overweight" rating on the stock with a €50 price target on July 17, citing the legal tailwind.

Yet the most critical procedural step remains unfinished. A $7.25 billion class-action settlement, provisionally approved in February, requires final court sign-off. The hearing originally scheduled for early July was postponed, and no new date has been set. Until that confirmation hearing takes place, the settlement — and the legal certainty it promises — is not a done deal.

Operating Momentum vs. Cash Flow Drain

Bayer's agricultural division, Crop Science, continues to show resilience despite a sharp drop in glyphosate sales. First-quarter group revenue reached €13.41 billion, with adjusted earnings per share of €2.71. Crop Science posted higher sales and a clear profit improvement, helped by an expected recovery in glyphosate volumes in Latin America during the second half. However, herbicide revenue slumped 10.2% and glyphosate-containing products fell 15.1%, as North American and European customers delayed purchases.

The free cash flow picture turned deeply negative: minus €2.32 billion in the first quarter, with net outflows of €2.0 billion tied to PCB and glyphosate settlement payments. Net financial debt rose 9.0% from the end of 2025 to €32.5 billion.

Fitch Holds Fire on Downgrade, Cites Litigation Cash Needs

On July 14, Fitch Ratings affirmed Bayer's long-term issuer default rating at "BBB" but kept the outlook at "negative." The agency pointed to expected cash outflows of $4 billion to $5 billion for litigation settlements this year, only partly offset by the $3 billion raised through the sale of a minority stake. The $5 billion bond placed on July 17, designed to refinance existing liabilities, does not change that calculus.

A New Growth Bet on Hybrid Wheat

On the operational front, Bayer signed an exclusive licensing agreement with France's RAGT on July 15 to tap elite wheat genetics for the European market. The company aims to build a hybrid wheat business targeting annual revenue of up to €1 billion by the early 2030s — a long-term growth pillar for Crop Science.

Bayer entered a quiet period on the same day ahead of its half-year results, due August 4. A crop science investor day is scheduled for September 2, and the annual shareholder meeting in April approved a dividend of €0.11 per share for 2025. CEO Bill Anderson reiterated the restructuring drive under the "Dynamic Shared Ownership" model.

The Next Catalyst: A Final Hearing With No Date

The stock has more than doubled from its 52-week low and now trades 73% above its level a year ago. Technical indicators show room to run, with the relative strength index not yet in overbought territory. But the investment case hinges heavily on the smooth conclusion of the settlement process. An uncontested final hearing would likely cement the upward trend; a further delay or unexpected objections could trigger sharp reversals in a stock that remains acutely sensitive to legal headlines.